Atrial Septal Defect Market - Forecasts from 2024 to 2029

The atrial septal defect market was valued at US$2.431 billion in 2022.

One of the most prevalent congenital heart diseases (CHDs) and the most prevalent CHD in adults is atrial septal defect (ASD). Over the past few decades, the therapy approach for ASD has undergone a paradigm change. Device closure of ASD is currently regarded as the treatment of choice in the majority of patients with secundum ASD, displaying great effectiveness as well as a decreased complication rate compared to surgery, as a consequence of the development and refinement of transcatheter treatment methods and devices.

Driving factors for the atrial septal defect market

The atrial septal defect industry is anticipated to grow due to the rising preference for minimally invasive procedures by patients and healthcare professionals. These innovations are less invasive and offer shorter hospital stays, quicker recuperation times, and minimum scarring. Various technological advancements have led to product innovations that enhance patient safety and clinical outcomes. Moreover, the increasing healthcare costs and growing public awareness of ASD treatments are some other factors fueling the atrial septal defect market growth.

Increasing prevalence of strokes

Stroke is considered the second leading cause of death worldwide. For instance, according to the Centers for Disease Control and Prevention in 2021, stroke was the cause of 1 in 6 fatalities from cardiovascular disease. A stroke occurs in the United States every 40 seconds and claims the life of a person every 3 minutes and 14 seconds. Over 795, 000 people in the US experience a stroke each year. Of them, about 610, 000 are new or first strokes, and nearly one in four strokes, or around 185, 000, occur in persons who have already had a stroke. Ischemic strokes, in which blood flow to the brain is interrupted, account for around 87% of all strokes. This growth will contribute to the growing market share for the atrial septal defect industry.

Rising awareness of different types of atrial septal defects

Growth in knowledge about various atrial septal defects plays a key role in the development of the market. Ostium secundum defect develops when the septum secundum does not completely occlude the ostium secundum or when there is greater reabsorption of the septum primum in the atrium's ceiling. Ostium primum defect is an atrial septal defect, which is the third most frequent, resulting from the septum primum's inability to merge with the endocardial cushions. Heart muscle's venous return is represented by the veins that make up the coronary sinus, an artery that runs along the groove between the left atrium and left ventricle. Above the septal leaflet of the tricuspid valve, it often drains onto the right atrium's floor.

Surgical closure treatment is anticipated to hold the maximum market share

Surgical closure treatment is predicted to rise significantly mainly due to its high success rate and long-term durability. During open-heart surgery, a patch or suture is used to patch up the defect and the hole in the heart is closed. Surgical closures are recommended for patients who have multiple abnormalities or any underlying heart condition. It is regarded as the gold standard for treating large and complex ASDs and is suitable for patients of all ages. Furthermore, catheter-based closures are anticipated to hold the second-largest atrial septal defect market share. This treatment entails a catheter threaded up to the heart through a tiny incision of the groin.

Enhancing healthcare team outcomes

Patients with atrial septal abnormalities require an interprofessional team with significant participation from the patient's paediatrician, primary care doctor, and nurse practitioner to improve healthcare team outcomes. The primary care physician often makes the first diagnosis of ASD before referring the patient to the cardiologist. Cardiologists regularly follow up with patients who have atrial septal defects in adults and children to check on the heart's anatomy, function, and hemodynamic condition.

In Asia Pacific, it is projected that the atrial septal defect market will grow steadily.

The atrial septal defect market is anticipated to grow in Asia Pacific during the projected period due to the rising prevalence of congenital cardiac conditions and the increasing need for ASD therapy. Medical tourism, an increase in healthcare infrastructure, and increased investment in the healthcare sector are the key factors fueling the atrial septal defect market growth in the Asia Pacific region. India and China are anticipated to hold the maximum market share in the Asia Pacific region owing to their vast population and growing disposable income.

Government regulations for the atrial septal defect market

• Through its Centre for Devices and Radiological Health (CDRH), the Food and Drug Administration (FDA) in the United States oversees medical devices used to identify and treat ASDs.
• Following the Medical Device Directive 93/42/EEC, the European Union has defined regulations for medical devices used in the diagnosis and treatment of ASDs.
• Governments are urged by theFramework Convention on Tobacco Control (FCTC) of the WHOto cut back on tobacco use and create regulations to safeguard the public's health from the negative effects of smoking.

Atrial Septal Defect Products

• Occlutech Figulla Flex II ASD Occluder, The third generation Occlutech device for ASD closure, the Figulla Flex II ASD Occluder (FSO, Occlutech GmbH, Jena, Germany), has a flexible titanium-oxide coated nitinol mesh and a double-disk construction identical to the ASO.
• Nit-Occlud ASD-R, The Nit-Occlud ASD-R (NOA-R) is a double-disk, self-expandable, self-centering device made by pfm Medical in Cologne, Germany, although it differs significantly from other nitrol-mesh devices in terms of its design features.

Market Key Developments

• In August 2022, InnAVasc Medical, Inc., a privately held medical technology company, was acquired by W. L. Gore & Associates, Inc. (Gore), a global material science company committed to transforming industries and improving lives.
• In July 2022, the launch of Qosina's AseptiQuik STC line of Steam-Thru connections was announced. The new line incorporates both the Steam-Thru II Steam-in-Place connector and the AseptiQuik sterile connector, giving manufacturers flexibility between hybrid stainless steel and single-use processing equipment.

Segmentation:

By Symptoms

• Frequent Respiratory Infections
• Swelling Legs and Feet
• Heart Palpitations
• Fatigue

By Diagnosis

• Chest X-ray
• Electrocardiogram

By End-User

• Hospitals
• Clinics
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others